New method could end fasting for cholesterol tests

Image
IANS New York
Last Updated : Jan 03 2018 | 6:51 PM IST

A new method of calculating so-called "bad cholesterol" levels has the potential to do away with the need to fast before blood is drawn for such screening, say researchers.

The study, published in the journal Circulation, suggests that the new method is more accurate than an older method in people who did not fast before the cholesterol test.

The new method for calculating LDL, or low-density lipoprotein, was developed by Seth Martin and colleagues at Johns Hopkins University School of Medicine in the US.

"Although the new LDL calculation method is a bit more complex, the beauty is that it can be performed using information that is already collected in the blood sample for the standard lipid profile and automated in the lab's computer system to give a more accurate result," Martin said.

"Since nonfasting samples are now accurate, it's more convenient for patients because they can come in anytime and don't need to return for a second appointment if they have eaten," Martin added.

For the study, the researchers compared the accuracy of the new LDL calculation method with the Friedewald method, developed in the late 1970s when patients fasted or did not fast.

The Friedewald method was earlier shown by Martin and colleagues to underestimate LDL cholesterol levels, particularly in people with high triglycerides.

Triglycerides are fatty acids that tend to be higher in people with obesity and diabetes and that increase after eating.

The physicians did their comparison using data already gathered in a clinical repository.

In their final analysis, the researchers found that approximately 30 per cent of the nonfasting participants had greater than 10 milligrams per decilitre inaccurate cholesterol measurements using the Friedewald method compared with only three per cent error from the actual measured value with the new method.

The new test does not take any longer to provide results to physicians and patients, and the cost is the same to administer, the study said.

--IANS

gb/dg

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jan 03 2018 | 6:34 PM IST

Next Story